Vanda Pharmaceuticals Inc. — Director's Dealing 2023

Jun 12, 2023

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Vanda Pharmaceuticals Inc. (VNDA)
CIK: 0001347178
Period of Report: 2023-06-08

Reporting Person: Honore Tage (Director)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2023-06-08	Common Stock	A	17307	$0.00	Acquired	43715	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2023-06-08	Stock Option (right to buy)	$6.50	A	33960	Acquired	2033-06-07	Common Stock (33960)	Direct

Footnotes

F1: Represents shares of common stock underlying a time-based restricted stock unit award (RSU). 100% of the shares subject to this RSU will vest on June 8, 2024, provided that the Reporting Person has provided continuous service to the Issuer through the vesting date.

F2: This option vests and becomes exercisable with respect to 100% of the option shares on June 8, 2024, provided that the Reporting Person has provided continuous service to the Issuer through the vesting date.